Abstract
Therapy management of colorectal tumors poses several problems. One of them is the differentiation between recurrent tumor and scar lesions in the follow up after potentially curative surgery. Morphologic methods like computed tomography (CT) and magnetic resonance imaging (MRI) provide superior information about the size and location of a space occupying lesion, but are often not helpful in the classification of a mass. Positron emission tomography (PET) has been used for diagnosis of recurrent brain tumors since years [1–3]. Furthermore, DiChiro et al. showed that metabolic studies in brain tumors can be useful for noninvasive tumor grading [3]. Employing whole body positron emission tomography, PET can be used for the diagnosis of recurrent tumors. By application of multiple radiopharmaceuticals information about perfusion and metabolism of recurrent tumors can be obtained. Furthermore, radiolabeled fluorouracil (FU) can be used to evaluate the kinetic and accumulation of this cytostatic agent prior to therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
DiChiro G, Oldsfield E, Bairamian D, Brooks RA, Patronas NJ, Mansi L, Kornblith PL, Smith BH, Sank VJ, Margolin RA: In vivo glucose utilization of tumors of the brain stem and spinal cord. In: Greitz T, Ingvar DH, Widen L, eds. Positron emission tomography. New York: Raven Press, 1985; 351–361.
DiChiro G: Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360–371.
DiChiro G, Hatazawa J, Katz DA, Rizzoli HV, DeMichele DJ: Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987; 164: 521–526.
Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623–648
Grabbe E, Winkler R: Local recurrence after sphincter-saving resection for rectal and rectosigmoid carcinoma: value of various diagnostic methods. Radiology 1985; 155: 305–310.
Johnson RJ, Jenkins JPR, Isherwood I, James D, Schofield PF: Quantitative magnetic resonance imaging in rectal carcinoma. Br J Radiol 1987; 60: 761–764.
Bischof-Delaloye A, Delaloye B, Buchegger F, Gilgien W, Studer A, Curchod S, Givel J-C, Mosimann F, Pettavel J, Mach J-P: Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 1989; 30: 1646–1656.
Köhne-Wömper C-H, Schmoll HJ, Harstrick A, Rustum YM: Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol Suppl. 3, 1992; 19: 105–125.
Abe Y, Fukuda H, Ishiwata K, Yoshioka S, Yamada K, Endo S, Kubota K, Sato T, Matsuzawa T, Takahashi T, Ido T: Studies on 18F-labeled pyrimidines. Tumor uptake of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-fluorodeoxyuridine in animals. Eur J Nucl Med 1983; 8: 258–261.
Strauss LG, Heim M, Jaschke W, Wetzel E, Schulze B, Beyer-Enke S, Georgi M: Intraarterielle Chemotherapie von kolorektalen Tumoren and Rezidiven. Tumor Diagnostik 0000Therapie 1986; 7: 225–230.
De Brauw LM, Marinelli A, van de Velde CJH, Hermans J, Tjaden UR, Erkelens C, de Bruijn EA: Pharmacological evalution of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Research 1991; 51: 1694–1700.
Hull WE, Port RE, Herrmann R, Britsch B, Kunz W: Metabolites of 5-Fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res 1988; 48: 1680–1688.
Shani J, Wolf W: A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]Fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. J Cancer Res 1977; 37: 2306–2308.
Wolf W, Presant CA, Kenneth LS, El-Tahtawy A, Albright MJ, Baker PB, Ring III R, Atkinson D, Ong R, King M, Singh M, Ray M, Wiseman C, Blayney D, Shani J. Tumor trapping of 5-fluorouracil: In vivo 19FNMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc Natl Acad Sci USA 1990; 87: 492–496.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Strauss, L.G. (1996). Assessment of Gastrointestinal Tumors with PET. In: Bares, R.B., Lucignani, G. (eds) Clinical PET. Developments in Nuclear Medicine, vol 28. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0309-8_5
Download citation
DOI: https://doi.org/10.1007/978-94-009-0309-8_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6624-2
Online ISBN: 978-94-009-0309-8
eBook Packages: Springer Book Archive